Tirzepatida: New Weight Loss Drug Coming to Mexico in June
Tirzepatide Approved in Mexico for Weight Management
Table of Contents
Mexican health authorities have recently approved tirzepatide, a drug previously used to treat type 2 diabetes, for weight management in adults.The pharmaceutical company Lilly, the productS manufacturer, anticipates the drug will be available in pharmacies by June 2025.
the decision to broaden the drug’s application stems from the Surmount-5 clinical trial, with findings presented at the European Congress on Obesity (ECO 2025). The study compared tirzepatide to semaglutide in adults with obesity or overweight.
Participants in the trial received either tirzepatide or semaglutide, alongside nutritional counseling and recommendations for physical activity.
Clinical Trial Results
The Surmount-5 study indicated that participants treated with tirzepatide experienced an average body weight reduction of 20.2% over 72 weeks, compared to a 13.7% reduction in those receiving semaglutide.
This 6.5 percentage point difference translates to an approximate additional weight loss of 7.8 kilograms per person.
Furthermore, 64.6% of participants using tirzepatide achieved at least a 15% reduction in their initial body weight, compared to 40.1% in the semaglutide group.
Obesity as a Public Health Concern
Obesity is recognized as a chronic disease affecting a critically important portion of the Mexican population.According to official figures, approximately 70% of adult Mexicans are classified as overweight or obese.
This condition is linked to a higher incidence of cardiovascular diseases, type 2 diabetes, and hypertension, among other health complications.
The clinical trial included adults with obesity or overweight who did not have a diabetes diagnosis but presented at least one comorbidity related to excess weight, such as sleep apnea, hypertension, or dyslipidemia.
Understanding Tirzepatide
Tirzepatide functions as a dual agonist of GIP and GLP-1 receptors,two hormones involved in regulating appetite,satiety,and glucose metabolism.
Its combined action has been the subject of various clinical trials to assess its effectiveness in promoting weight loss and improving metabolic control.
The Surmount-5 study, a phase 3b double-blind trial, compared tirzepatide (at a 15 mg dose) with semaglutide (2.4 mg), which is currently approved in Mexico for obesity treatment.
Availability and Monitoring
The approved use of tirzepatide for weight management requires a medical prescription. Lilly anticipates the drug’s availability in Mexico starting in june 2025.
Training programs for medical professionals are expected in the coming months to familiarize them with the drug’s clinical profile and prescription guidelines.
Tirzepatide is now patented as a therapeutic option for managing body weight in adults with obesity or overweight.However, its use should be evaluated on a case-by-case basis under medical supervision.
Tirzepatide for weight Loss in Mexico: Your Questions Answered
Focusing on Experience, Expertise, Authoritativeness, and Trustworthiness (E-E-A-T) to ensure comprehensive and accurate data.
Q: What is tirzepatide and why is it making news in Mexico?
A: Tirzepatide is a medication that has recently been approved in Mexico for weight management in adults.Initially used to treat type 2 diabetes, the drug’s application is now expanding to help individuals struggling with obesity and overweight. The pharmaceutical company lilly, the manufacturer, anticipates that tirzepatide will be available in mexican pharmacies starting in June 2025.
Q: How does tirzepatide work for weight loss?
A: Tirzepatide functions as a dual agonist of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. These are two hormones involved in regulating appetite, satiety, and glucose metabolism. Its combined action helps in promoting weight loss and improving metabolic control.
Q: What is the Surmount-5 clinical trial, and what did it reveal about tirzepatide?
A: the Surmount-5 study, a phase 3b double-blind trial, compared tirzepatide (at a 15 mg dose) to semaglutide (2.4 mg), a drug already approved in Mexico for obesity treatment. Findings from the trial,presented at the European Congress on Obesity (ECO 2025),showed that participants treated with tirzepatide experienced meaningful weight loss.
Q: What were the results of the Surmount-5 trial comparing Tirzepatide and Semaglutide?
| Feature | Tirzepatide (15 mg) | Semaglutide (2.4 mg) | Difference |
|——————-|———————–|———————–|———————-|
| average Weight Reduction (72 weeks) | 20.2% | 13.7% | 6.5 percentage points (approx. 7.8 kg) |
| ≥15% Weight Reduction | 64.6% | 40.1% | N/A |
Q: How significant is the weight loss observed with tirzepatide?
A: The Surmount-5 study highlighted an average body weight reduction of 20.2% over 72 weeks for those taking tirzepatide, compared to 13.7% for semaglutide. This means that, on average, patients in the tirzepatide group lost approximately 7.8 kilograms more than those in the semaglutide group. Furthermore, a larger percentage of participants (64.6%) using tirzepatide achieved at least a 15% reduction in their initial body weight, compared to 40.1% in the semaglutide group.
Q: Why is obesity a major health concern in Mexico?
A: Obesity is recognized as a chronic disease that affects a critically significant portion of the Mexican population. According to official figures, approximately 70% of adult Mexicans are classified as overweight or obese. This condition substantially increases the risk of cardiovascular diseases, type 2 diabetes, hypertension, and other serious health complications.
Q: Who was included in the clinical trial?
A: The clinical trial included adults with obesity or overweight who did not have a diabetes diagnosis. However, participants presented at least one comorbidity related to excess weight, such as sleep apnea, hypertension, or dyslipidemia.
Q: How can I get tirzepatide in Mexico?
A: the approved use of tirzepatide for weight management requires a medical prescription. The drug’s availability in Mexico is anticipated to begin in June 2025.You must consult a healthcare professional who can assess your individual case and,if appropriate,prescribe the medication. Its use should always be under medical supervision.
Q: are any specific guidelines or trainings planned for medical professionals?
A: Yes,training programs for medical professionals are expected in the coming months. These programs are designed to familiarize healthcare providers with tirzepatide’s clinical profile and prescription guidelines, ensuring its safe and effective use.